THE SYMBOL [***] DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH COMPANY IF PUBLICLY DISCLOSED. PROFIT RIGHT AND WAIVER AGREEMENT among NEWAMSTERDAM PHARMA B.V. and DEZIMA PHARMA B.V. and...Profit Right and Waiver Agreement • September 13th, 2022 • NewAmsterdam Pharma Co B.V. • Pharmaceutical preparations • New York
NewAmsterdam Pharma Holding B.V. Gooimeer 2-35 1411 DC Naarden The Netherlands Naarden, 20 July 2022 BY ELECTRONIC TRANSMISSION Mitsubishi Tanabe Pharma CorporationProfit Right and Waiver Agreement • September 13th, 2022 • NewAmsterdam Pharma Co B.V. • Pharmaceutical preparations
Reference is made to the profit right and waiver agreement among Mitsubishi Tanabe Pharma Corporation (“MTPC” or “you”), NewAmsterdam Pharma Holding B.V. (formerly NewAmsterdam Pharma B.V.) (“NAP” or “us”) and Dezima Pharma B.V. (the “Company”) dated 9 April 2020 regarding the waiver by MTPC of certain then-existing rights in connection with the acquisition of all shares in the share capital of the Company by Saga Investments Coöperatief U.A. (the “Agreement”). Unless stated otherwise herein, capitalized terms used in this letter agreement shall have the same meaning as ascribed thereto in the Agreement.
